Angiogenesis in bone marrow of myelodysplastic syndrome patients;Angiogeneza w szpiku kostnym u chorych na zespoły mielodysplastyczne

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue 4, 2007, Pages 25-30

  Ma̧dry, Krzysztof ^a,b   Dwilewicz Trojaczek, Jadwiga ^a   Suleiman, Wael ^a   Paszkowska Kowalewska, Małgorzata ^a   Ziarkiewicz Wróblewska, Bogna ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NONE   (Poland)

Author keywords

Angiogenesis; Microvessel density; Myelodysplastic syndromes; Vascular endothelial growth factor

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; MONOCLONAL ANTIBODY; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MICROVASCULATURE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SOLID TUMOR;

EID: 34547808247     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182-1187.
2. Ellis LM, Fiedler IJ. Angiogenesis and metastasis. Eur J Cancer. 1996; 32A: 2451-2455.
3. Gasparini G. Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur J Cancer. 1996; 32A: 2458.
4. Graham CH, Rivers J, Kerbel RS, et al. Extent of vascularisation as a prognostic indicator in thin (<0,076 mm) malignant melanoma. Am J Pathol. 1994; 145: 510.
5. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Patol. 1993; 143: 401.
6. Vacca A, Di Loreto M, Ribatti D, et al. Bone marrow of patients with active multiple myeloma. Angiogenesis and plasma cell adhesion molecules LFA-1,VLA-4, LAM-1 and CD44. Am J Hematol. 1995; 50: 9-14.
7. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concetration is associated with poor outcome in non-Hodgin's lymphoma. Blood. 1997; 90: 3167-3172.
8. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001; 97: 1427-1434.
9. Aguayo A, Kantarjian HM, Estey EH, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002; 95: 1923-1930.
10. Korkolopoulou P, Apostolidou E, et al. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia. 2001; 15: 1369-1376.
11. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000; 96: 2240-2245.
12. Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999; 8: 1398-1401.
13. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000; 95: 309-313.
14. Smolich BD, Yuem HE, West K, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU 6668 inhibit the SCF receptor (c-kit) in human myeloid leukemia cell line and in acute leukemia blasts. Blood. 2001; 97: 1413-1421.
15. Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Hematol. 2001; 115: 881-894.